Increasing Numbers of Launches and Growth in Spending on Specialty Products i...IMS Health US
The specialty products share of the R&D pipeline has increased 9% in the past decade, driven by drugs targeting cancer, nervous system disorders, infectious diseases, diabetes and respiratory disorders.
Medicines Use and Spending Shifts: A Review of the Use of MedicinesIMS Health US
Growth in spending on medicines was higher in 2014 than any year since 2001, and
exceeded forecast overall healthcare spending growth for the first time since 2011.
As 2014 was also a landmark year in the implementation of the Affordable Care Act,
understanding the specific drivers of medicine spending growth is important for decisionmakers
across the healthcare system.
In this report we bring together several perspectives on 2014: total system spending on
medicines at an aggregate and segmented level; the evolution of healthcare demand, delivery
and payment systems; patient out-of-pocket costs for medical and pharmacy benefits including
retail prescription co-pays; and transformations in disease treatment resulting from newly
approved medicines.
Increasing Numbers of Launches and Growth in Spending on Specialty Products i...IMS Health US
The specialty products share of the R&D pipeline has increased 9% in the past decade, driven by drugs targeting cancer, nervous system disorders, infectious diseases, diabetes and respiratory disorders.
Medicines Use and Spending Shifts: A Review of the Use of MedicinesIMS Health US
Growth in spending on medicines was higher in 2014 than any year since 2001, and
exceeded forecast overall healthcare spending growth for the first time since 2011.
As 2014 was also a landmark year in the implementation of the Affordable Care Act,
understanding the specific drivers of medicine spending growth is important for decisionmakers
across the healthcare system.
In this report we bring together several perspectives on 2014: total system spending on
medicines at an aggregate and segmented level; the evolution of healthcare demand, delivery
and payment systems; patient out-of-pocket costs for medical and pharmacy benefits including
retail prescription co-pays; and transformations in disease treatment resulting from newly
approved medicines.
Prescription Medicines - Costs in Context - October 2018PhRMA
Discussions about costs are important. We recognize that many are struggling to access the medicine they need, and have important questions about their medicine costs. And we want to help find the answers.
When: June 10, 2021
Only 5% of rare diseases have an approved drug therapy. Only 60% of orphan medicines approved by the US FDA or EU EMA are approved in Canada, and often many months or years later. Only 34% of approved orphan medicines are funded by Canadian public drug plans. Under the BEST of circumstances, only 10% of eligible patients get access to an approved medicine. And worldwide, only 1% of rare disease patients will receive an approved drug. Most without treatment are children. How can Canada’s Rare Disease Drug Strategy assure all eligible Canadian patients get access to the most appropriate medicine for their individual needs?
Two panels will be tasked to consider a “Canada Leading the Way” strategic pharmaceutic framework that (1) attracts early investment in R&D; (2) reduces and manages risk for early adoption of innovative therapies; and (3) leads to a sustained culture of collaboration and trust among all stakeholders, including regulators, industry, payers, and patients. In particular, what has Canada learned from addressing COVID, for example, in terms of screening, diagnosis, drug repurposing, vaccine procurement, timely intervention, and monitoring, that can apply directly to rare disease therapies?
August 19, 2021 from 1-2 pm
CORD’s LAST SUMMER webinar, Part 1 of our series on “How to Get Back to the PMPRB Original Mandate to prevent excessive drug pricing and support pharma R&D investment.” Learn why responding to the most recent (July 15th) proposed guideline changes is very important.
On August 19, 2021 from 1-2 pm, please JOIN:
July 22, 2021 : Aligning on Rare Drug Strategy, PMPRB, and Federal Election
Engage with our Expert Panel in a Townhall style meeting to add your voice on these important issues in preparation for upcoming federal election.
Panelist
Alexandra Chambers (Novartis)
Peter Brenders (BeiGene)
Angela Genge (The Neuro)
Fred Horne (3Sixty Public Affairs)
Leanne Ward (CHEO)
Presentation delivered by Dr Kathleen Bennett, Department of Pharmacology and Therapeutics, Trinity Centre for Health Sciences, St James’s Hospital at the Irish Pharmaceutical Healthcare Association Meeting 2009.
Global Medicines Use in 2020: Outlook and ImplicationsQuintilesIMS
The global use of medicines will reach 4.5 trillion doses by 2020 costing $1.4 trillion. The largest pharmaceutical-using countries will be the pharmerging markets, accounting for two-thirds of the global medicine volumes, mostly comprised of generic medicines and reflecting dramatic increases in utilization of medicines due to broad-based health system expansions. Medicines in 2020 will include a vast array of treatments ranging from those that provide symptom relief available without a prescription to lifesaving genetically personalized therapies unique to a single patient. Disease treatments in 2020 will be transformed by the increased number and quality of new medicines in clusters of innovation around cancer, Hepatitis C, autoimmune disorders, heart disease and an array of rare diseases. By 2020, technology will be enabling more rapid changes to treatment protocols, increasing patient engagement and accountability, shifting patient-provider interaction, and accelerating the adoption of behavior changes that will improve patient adherence to treatments.
Presentation on understanding to what extent medicine prices impact on the challenges of access to medicines in a country, by Denis Kibira, HEPS Uganda, during MeTA CSO workshop, April 2009.
The Future of the Generics Industry, facilitated by Luigi Martini of Kings College London.
A presentation by Jo Pisani of PWC at Pharma Integrates 2013, an event for senior management in the pharmaceutical industry created and run by Life Sciences Index.
Listeners participated in a live panel session addressing OHIP+, the recently announced expansion of the Ontario drug program to cover young people who are younger than 25 years-old.
Webinar 3: Alternative Approaches to Innovative Drug Pricing – 12:00pm on Wednesday, May 13, 2020. The third webinar will review Canada’s approach to managing drug prices with approaches used in other jurisdictions. A panel will discuss experiences with oncology therapies, rare disease drugs, and therapies for pandemics and other urgent situations as points of reference toward evolving alternatives to the proposed PMPRB guidelines.
Panel:
Martina Garau, Director, Office of Health Economics, UK;
Sandra Anderson, Senior VP, Innomar Strategies
PG Forest, Director, School of Public Policy, University of Calgary
Durhane Wong-Rieger, President & CEO, CORD
Moderator: Bill Dempster, 3Sixty Public Affairs
Prescription Medicines - Costs in Context - October 2018PhRMA
Discussions about costs are important. We recognize that many are struggling to access the medicine they need, and have important questions about their medicine costs. And we want to help find the answers.
When: June 10, 2021
Only 5% of rare diseases have an approved drug therapy. Only 60% of orphan medicines approved by the US FDA or EU EMA are approved in Canada, and often many months or years later. Only 34% of approved orphan medicines are funded by Canadian public drug plans. Under the BEST of circumstances, only 10% of eligible patients get access to an approved medicine. And worldwide, only 1% of rare disease patients will receive an approved drug. Most without treatment are children. How can Canada’s Rare Disease Drug Strategy assure all eligible Canadian patients get access to the most appropriate medicine for their individual needs?
Two panels will be tasked to consider a “Canada Leading the Way” strategic pharmaceutic framework that (1) attracts early investment in R&D; (2) reduces and manages risk for early adoption of innovative therapies; and (3) leads to a sustained culture of collaboration and trust among all stakeholders, including regulators, industry, payers, and patients. In particular, what has Canada learned from addressing COVID, for example, in terms of screening, diagnosis, drug repurposing, vaccine procurement, timely intervention, and monitoring, that can apply directly to rare disease therapies?
August 19, 2021 from 1-2 pm
CORD’s LAST SUMMER webinar, Part 1 of our series on “How to Get Back to the PMPRB Original Mandate to prevent excessive drug pricing and support pharma R&D investment.” Learn why responding to the most recent (July 15th) proposed guideline changes is very important.
On August 19, 2021 from 1-2 pm, please JOIN:
July 22, 2021 : Aligning on Rare Drug Strategy, PMPRB, and Federal Election
Engage with our Expert Panel in a Townhall style meeting to add your voice on these important issues in preparation for upcoming federal election.
Panelist
Alexandra Chambers (Novartis)
Peter Brenders (BeiGene)
Angela Genge (The Neuro)
Fred Horne (3Sixty Public Affairs)
Leanne Ward (CHEO)
Presentation delivered by Dr Kathleen Bennett, Department of Pharmacology and Therapeutics, Trinity Centre for Health Sciences, St James’s Hospital at the Irish Pharmaceutical Healthcare Association Meeting 2009.
Global Medicines Use in 2020: Outlook and ImplicationsQuintilesIMS
The global use of medicines will reach 4.5 trillion doses by 2020 costing $1.4 trillion. The largest pharmaceutical-using countries will be the pharmerging markets, accounting for two-thirds of the global medicine volumes, mostly comprised of generic medicines and reflecting dramatic increases in utilization of medicines due to broad-based health system expansions. Medicines in 2020 will include a vast array of treatments ranging from those that provide symptom relief available without a prescription to lifesaving genetically personalized therapies unique to a single patient. Disease treatments in 2020 will be transformed by the increased number and quality of new medicines in clusters of innovation around cancer, Hepatitis C, autoimmune disorders, heart disease and an array of rare diseases. By 2020, technology will be enabling more rapid changes to treatment protocols, increasing patient engagement and accountability, shifting patient-provider interaction, and accelerating the adoption of behavior changes that will improve patient adherence to treatments.
Presentation on understanding to what extent medicine prices impact on the challenges of access to medicines in a country, by Denis Kibira, HEPS Uganda, during MeTA CSO workshop, April 2009.
The Future of the Generics Industry, facilitated by Luigi Martini of Kings College London.
A presentation by Jo Pisani of PWC at Pharma Integrates 2013, an event for senior management in the pharmaceutical industry created and run by Life Sciences Index.
Listeners participated in a live panel session addressing OHIP+, the recently announced expansion of the Ontario drug program to cover young people who are younger than 25 years-old.
Webinar 3: Alternative Approaches to Innovative Drug Pricing – 12:00pm on Wednesday, May 13, 2020. The third webinar will review Canada’s approach to managing drug prices with approaches used in other jurisdictions. A panel will discuss experiences with oncology therapies, rare disease drugs, and therapies for pandemics and other urgent situations as points of reference toward evolving alternatives to the proposed PMPRB guidelines.
Panel:
Martina Garau, Director, Office of Health Economics, UK;
Sandra Anderson, Senior VP, Innomar Strategies
PG Forest, Director, School of Public Policy, University of Calgary
Durhane Wong-Rieger, President & CEO, CORD
Moderator: Bill Dempster, 3Sixty Public Affairs
Prescription Medicines - Costs in Context - August 2018PhRMA
Discussions about the cost and affordability of medicines – and health care more broadly – are important. At the same time, it is important to look at costs across the health care system and not just the share going toward life changing medicines.
Prescription Medicines Costs in Context - June 2019PhRMA
We are in a new era of medicine where breakthrough science is transforming care with innovative treatment approaches and enabling us to more effectively treat chronic disease, the biggest cost driver.
Prescription Medicines - Costs in Context January 2019PhRMA
Discussions about costs are important. We recognize that many are struggling to access the medicine they need, and have important questions about their medicine costs. And we want to help find the answers.
Prescription Medicines - Costs In Context March 2019PhRMA
Discussions about costs are important. We recognize that many are struggling to access the medicine they need, and have important questions about their medicine costs. And we want to help find the answers.
Does Price Discrimination Have a Place in Pharmaceutical Pricing in Developin...Office of Health Economics
At iHEA 2013, OHE's Adrian Towse participated in a session on implementing differential pricing schemes. He discussed the role of price discrimination strategies, including the use of discounts, access programmes and risk sharing agreements in increasing the number of patients who can benefit from new medications in LMICs. Real life examples illustrated differential pricing schemes between and within countries and provided background for exploring feasibility—particularly about how options relying on confidentiality and negotiation compare with those based on collaborative international agreement about how price differentiation is developed and implemented.
Nasal Drug Delivery Technology Market Report AnalysisAryanRaj496746
Nasal drug has been extensively used and due to its efficacy its popularity is rising. Research and development has helped in making it more effective with less and less harm. This report talks about different market aspect of Nasal Drug Delivery Technology. Market drivers that can affect its growth and Delvens' analyst view on this market.
Prescription Medicines - Costs in Context - September 2018PhRMA
Discussions about costs are important. We recognize that many are struggling to access the medicine they need, and have important questions about their medicine costs. And we want to help find the answers.
Prescription Medicines - Costs in Context - September 2018PhRMA
Discussions about costs are important. We recognize that many are struggling to access the medicine they need, and have important questions about their medicine costs. And we want to help find the answers.
Please share this video with anyone who may be interested!
Watch all our webinars: https://www.youtube.com/playlist?list=PL4dDQscmFYu_ezxuxnAE61hx4JlqAKXpR
In this webinar:
● Takeaways from a roundtable held on June 1st about patient-centred pharmacare in Canada
● Reports from patient groups and other subject matter experts
● A cohesive vision and set of values for national pharmacare in Canada
View the video: https://youtu.be/HMy_gsTDkfI
Follow our social media accounts:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Pinterest - https://www.pinterest.com/survivornetwork
YouTube - https://www.youtube.com/user/Survivornetca
its not my personal work presentation but taken from lecture ppt from university of San Diego, california.
Its about the drug discovery process, its development and its commercialization.
The New Pharma Ecosystem: 2014 Trends Reshaping the Pharmaceutical Supply ChainLaura Olson
The pharmaceutical industry is undergoing tremendous changes. Numerous forces are re-shaping the new pharmaceutical ecosystem. Technology, demographics, regulations and shifts in wealth are creating transformative change. Increasingly becoming a more patient-centric world, patients use Smart devices to monitor research and evaluate pharmaceutical products. Healthcare reform regulations, the devaluation of the existing pharma model and trend towards patient empowerment and access to information are shaping the changing pharma industry, much as the retail industry was shaped by the multichannel and omni channel retailing trends of recent years. Regulators have become increasingly more cautious when improving innovative medicines. As pharmaceuticals have become more successful in prolonging life and treating illness, many medical conditions are now chronic. Today healthcare providers have become increasingly interested in measuring the outcomes of pharma performance and basing pricing accordingly. There has been a dramatic increase in prescription volume and an increased production and use of generic drugs. Producing pharmaceuticals in other countries can be complicated. Customs, local regulations and other factors impact products and require brands to adapt. Generic pharmaceuticals are becoming the dominant category globally, especially in developing rather than just industrial countries. Adding to the complexity, a large number of pharmaceutical products are made by multiple countries. These factors and the move towards specialty pharmaceuticals and greater production of pharmaceutical products globally have resulted in more pressure on global supply chains. Because supply chains have moved from local to global in operation, even one significant event can interrupt the global supply chain. Events such as hurricanes and typhoons, earthquakes, political and economic upheaval can have serious impacts on global supply chains, adding unforeseen costs and delays. Health care reform magnifies the effect of longer supply chains and increases the intense cost pressure on drug manufacturers. In order to reduce costs, more production as well as research and development are being offshored and outsourced.
Feeding plate for a newborn with Cleft Palate.pptxSatvikaPrasad
A feeding plate is a prosthetic device used for newborns with a cleft palate to assist in feeding and improve nutrition intake. From a prosthodontic perspective, this plate acts as a barrier between the oral and nasal cavities, facilitating effective sucking and swallowing by providing a more normal anatomical structure. It helps to prevent milk from entering the nasal passage, thereby reducing the risk of aspiration and enhancing the infant's ability to feed efficiently. The feeding plate also aids in the development of the oral muscles and can contribute to better growth and weight gain. Its custom fabrication and proper fitting by a prosthodontist are crucial for ensuring comfort and functionality, as well as for minimizing potential complications. Early intervention with a feeding plate can significantly improve the quality of life for both the infant and the parents.
Letter to MREC - application to conduct studyAzreen Aj
Application to conduct study on research title 'Awareness and knowledge of oral cancer and precancer among dental outpatient in Klinik Pergigian Merlimau, Melaka'
Chandrima Spa Ajman is one of the leading Massage Center in Ajman, which is open 24 hours exclusively for men. Being one of the most affordable Spa in Ajman, we offer Body to Body massage, Kerala Massage, Malayali Massage, Indian Massage, Pakistani Massage Russian massage, Thai massage, Swedish massage, Hot Stone Massage, Deep Tissue Massage, and many more. Indulge in the ultimate massage experience and book your appointment today. We are confident that you will leave our Massage spa feeling refreshed, rejuvenated, and ready to take on the world.
Visit : https://massagespaajman.com/
Call : 052 987 1315
PET CT beginners Guide covers some of the underrepresented topics in PET CTMiadAlsulami
This lecture briefly covers some of the underrepresented topics in Molecular imaging with cases , such as:
- Primary pleural tumors and pleural metastases.
- Distinguishing between MPM and Talc Pleurodesis.
- Urological tumors.
- The role of FDG PET in NET.
Stem Cell Solutions: Dr. David Greene's Path to Non-Surgical Cardiac CareDr. David Greene Arizona
Explore the groundbreaking work of Dr. David Greene, a pioneer in regenerative medicine, who is revolutionizing the field of cardiology through stem cell therapy in Arizona. This ppt delves into how Dr. Greene's innovative approach is providing non-surgical, effective treatments for heart disease, using the body's own cells to repair heart damage and improve patient outcomes. Learn about the science behind stem cell therapy, its benefits over traditional cardiac surgeries, and the promising future it holds for modern medicine. Join us as we uncover how Dr. Greene's commitment to stem cell research and therapy is setting new standards in healthcare and offering new hope to cardiac patients.
International Cancer Survivors Day is celebrated during June, placing the spotlight not only on cancer survivors, but also their caregivers.
CANSA has compiled a list of tips and guidelines of support:
https://cansa.org.za/who-cares-for-cancer-patients-caregivers/
KEY Points of Leicester travel clinic In London doc.docxNX Healthcare
In order to protect visitors' safety and wellbeing, Travel Clinic Leicester offers a wide range of travel-related health treatments, including individualized counseling and vaccines. Our team of medical experts specializes in getting people ready for international travel, with a particular emphasis on vaccines and health consultations to prevent travel-related illnesses. We provide a range of travel-related services, such as health concerns unique to a trip, prevention of malaria, and travel-related medical supplies. Our clinic is dedicated to providing top-notch care, keeping abreast of the most recent recommendations for vaccinations and travel health precautions. The goal of Travel Clinic Leicester is to keep you safe and well-rested no matter what kind of travel you choose—business, pleasure, or adventure.
About this webinar: This talk will introduce what cancer rehabilitation is, where it fits into the cancer trajectory, and who can benefit from it. In addition, the current landscape of cancer rehabilitation in Canada will be discussed and the need for advocacy to increase access to this essential component of cancer care.
This document is designed as an introductory to medical students,nursing students,midwives or other healthcare trainees to improve their understanding about how health system in Sri Lanka cares children health.
Rate Controlled Drug Delivery Systems, Activation Modulated Drug Delivery Systems, Mechanically activated, pH activated, Enzyme activated, Osmotic activated Drug Delivery Systems, Feedback regulated Drug Delivery Systems systems are discussed here.
Trauma Outpatient Center is a comprehensive facility dedicated to addressing mental health challenges and providing medication-assisted treatment. We offer a diverse range of services aimed at assisting individuals in overcoming addiction, mental health disorders, and related obstacles. Our team consists of seasoned professionals who are both experienced and compassionate, committed to delivering the highest standard of care to our clients. By utilizing evidence-based treatment methods, we strive to help our clients achieve their goals and lead healthier, more fulfilling lives.
Our mission is to provide a safe and supportive environment where our clients can receive the highest quality of care. We are dedicated to assisting our clients in reaching their objectives and improving their overall well-being. We prioritize our clients' needs and individualize treatment plans to ensure they receive tailored care. Our approach is rooted in evidence-based practices proven effective in treating addiction and mental health disorders.
1. HEALTHCARE COSTS AND SPENDING ON MEDICINES
Page 12
Source: IMS Health, National Sales Perspectives, Dec 2014
43.4
38.5
36.335.7
34.9
Supportive Care Cytotoxics Hormonal TherapiesTargeted Therapies
2010 2011 2012 2013 2014
12.3 11.6 10.7 10.7 11.1
7.4 7.7
7.0 6.5 6.5
12.6 14.4 16.7 19.1
22.9
2.6 2.0 1.9
2.2
2.9
Oncologics spending reached $43.4 billion in 2014 lifted by
new melanoma, lung, breast and prostate cancer therapies
Therapeutic Oncology and Supportive Care Spending US$Bn
•• Oncologics led all classes in spending in
2014 with $32.3Bn in spending, or $43.4Bn
including supportive care treatments.
•• Spending grew by nearly $4.9Bn, mostly
from new targeted therapies, which had the
fourth straight year of $1Bn or more growth
from new brands, and many of those earlier
medicines have continued to expand usage
and contribute more to spending.
•• Treatment options launched in the last two
years account for 30% of spending increases.
•• Supportive care treatments such as
erythropoeitins, anti-nauseants, and
bisphosphonates contributed little to
spending growth but often allow patients to
continue on other treatments.
•• Granix, a non-original version of the biologic
Neupogen, used to reduce the risk of infection
during chemotherapy, became available in
November 2013 and now accounts for 11% of
filgrastim volumes.
Chart notes:
Therapeutic oncology defined as EphMRA ATC classification L1 - cytotoxics, L2 hormonal treatments, V3C radiotherapeutics, as well as molecules
classified elsewhere noted to be therapeutic oncolgoics (lenalidomide, denosumab (when used for bone metastases it is marketed as Xgeva),
aldesleukin, pomalidomide). Supportive care includes erythropoeitins, colony-stimulating factors, anti-nauseants for cancer, and chemotherapy
protectants.
Medicines Use and Spending Shifts. Report by the IMS Institute for Healthcare Informatics.